TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24733796

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1) 3.6 mg/kg plus pertuzumab (840-mg loading dose, then 420 mg subsequently) every 3 weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1) plus pertuzumab
Number of subjects: 64
Study: 24735977

Group type: EXPERIMENTAL
Intervention: Acetylcholine iontophoresis (0.1 mA, 30s) at inter-electrode distance of 5 cm
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Acetylcholine iontophoresis (0.1 mA, 30s) at inter-electrode distance of 10 cm
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Acetylcholine iontophoresis (0.1 mA, 30s) at inter-electrode distance of 15 cm
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Acetylcholine iontophoresis
Number of subjects: 14
Study: 24736052

Group type: EXPERIMENTAL
Intervention: Surgical closure of macular hole
Number of subjects: 35
Study: 24736094

Group type: EXPERIMENTAL
Intervention: Theory-based, culturally congruent health-promotion intervention encouraging physical activity
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Attention-matched HIV/STI risk-reduction control intervention
Number of subjects: 1106
Study: 24737128

Group type: EXPERIMENTAL
Intervention: cMethDNA assay
Number of subjects: 29
Study: 24737778

Group type: EXPERIMENTAL
Intervention: Tivantinib 360 mg b.i.d. with gemcitabine 1000 mg/m(2) weekly for 3 of 4 weeks
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Tivantinib 360 mg b.i.d. with gemcitabine
Number of subjects: 29
Study: 24738612

Group type: EXPERIMENTAL
Intervention: DCE MR imaging using parametric response map (PRM) analysis
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pharmacokinetic parameters (K(trans), kep, and ve)
Number of subjects: 48
Study: 24738629

Group type: EXPERIMENTAL
Intervention: Idarubicin-loaded beads (2 mL drug-eluting beads; DC Bead 300-500 μm) at 5 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Idarubicin-loaded beads (2 mL drug-eluting beads; DC Bead 300-500 μm) at 10 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Idarubicin-loaded beads (2 mL drug-eluting beads; DC Bead 300-500 μm) at 15 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Idarubicin-loaded beads (2 mL drug-eluting beads; DC Bead 300-500 μm)
Number of subjects: 21
Study: 24738870

Group type: EXPERIMENTAL
Intervention: Chronic periodontitis in CKD patients
Number of subjects: 500

Group type: COMPARATOR
Intervention: ADHS sample (control)
Number of subjects: 500
Study: 24739099

Group type: EXPERIMENTAL
Intervention: Palaeolithic-type diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nordic Nutrition recommendations diet
Number of subjects: 12
Study: 24739633

Group type: EXPERIMENTAL
Intervention: Poly (I:C) TLR3 ligand stimulation in HT-29 cells
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Colonic biopsies from IBD patients
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Active IBD
Number of subjects: 133
Study: 24739897

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day
Number of subjects: 67
Study: 24739978

Group type: EXPERIMENTAL
Intervention: Nonadjuvanted cell culture-derived whole-virus H5N1 vaccine; two priming immunizations with clade 1 A/Vietnam H5N1 vaccine, booster with clade 2.1 A/Indonesia H5N1 vaccine 12 to 24 months later.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T-cell responses assessed by ELISPOT in immunocompromised patients.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Safety and tolerability of the vaccine.
Number of subjects: 0
Study: 24740809

Group type: EXPERIMENTAL
Intervention: Postinduction MRD level ≥10(-4)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Unfavorable genetic characteristics (MLL gene rearrangement or focal IKZF1 gene deletion in BCP-ALL; no NOTCH1/FBXW7 mutation and/or N/K-RAS mutation and/or PTEN gene alteration in T-cell ALL)
Number of subjects: 423
Study: 24740992

Group type: EXPERIMENTAL
Intervention: Continuous non-invasive measurement using a finger cuff (MAPcNIAP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intermittent arm cuff oscillometry (MAPiNIAP)
Number of subjects: 120
Study: 24741582

Group type: EXPERIMENTAL
Intervention: Rituximab monotherapy (4 weekly doses)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Rituximab monotherapy followed by CHOP-21 (16 out of 25 patients)
Number of subjects: 25
Study: 24742013

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2313
Study: 24742768

Group type: EXPERIMENTAL
Intervention: Tadalafil 40 mg/d
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sildenafil
Number of subjects: 35
Study: 24742874

Group type: EXPERIMENTAL
Intervention: Physical activity assessed by counts/minute (median 244.37)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Vigorous activity daytime
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Sedentary activity daytime
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Moderate and vigorous activity
Number of subjects: 263
Study: 24743000

Group type: EXPERIMENTAL
Intervention: rAvPAL-PEG (0.100 mg/kg)
Number of subjects: 25
Study: 24743391

Group type: EXPERIMENTAL
Intervention: Long-term parenteral nutrition (PN)
Number of subjects: 27
Study: 24743708

Group type: EXPERIMENTAL
Intervention: First-line trastuzumab use
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: First-line taxane use
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: HER2-positive MBC patient profile
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 244
Study: 24743713

Group type: EXPERIMENTAL
Intervention: Citalopram/Escitalopram for up to 8 weeks
Number of subjects: 0
Study: 24743720

Group type: EXPERIMENTAL
Intervention: Patients' rated illness severity scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinicians' rated illness severity scores
Number of subjects: 0
Study: 24744276

Group type: EXPERIMENTAL
Intervention: Internal mammary artery (IMA) occlusion during coronary artery balloon occlusion
Number of subjects: 120

Group type: COMPARATOR
Intervention: No IMA occlusion during coronary artery balloon occlusion
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Left IMA with left anterior descending artery occlusion
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Right IMA with right coronary artery occlusion
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Right IMA with left anterior descending artery occlusion
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Left IMA with right coronary artery occlusion
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ipsilateral IMA occlusions
Number of subjects: 120

Group type: COMPARATOR
Intervention: Contralateral IMA occlusions
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Left circumflex artery occlusions with either IMA
Number of subjects: 120
Study: 24745306

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Recovery index
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 74
Study: 24746173

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study: 24746569

Group type: EXPERIMENTAL
Intervention: Blood biomarkers (CEA, CA19-9, LDH, CRP, IL-6, IL-8, CA IX, osteopontin, 25-OH-vitamin D)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Blood biomarkers (CEA, IL-8, osteopontin)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: CEA and IL-8
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Biomarker model
Number of subjects: 295
Study: 24746650

Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable vascular scaffold (BVS)
Number of subjects: 136

Group type: COMPARATOR
Intervention: everolimus-eluting metal stents (EES)
Number of subjects: 136
Study: 24746841

Group type: EXPERIMENTAL
Intervention: MABp1 (anti-interleukin-1α monoclonal antibody) at 3.75 mg/kg every 2 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: MABp1 (anti-interleukin-1α monoclonal antibody)
Number of subjects: 52
Study: 24747207

Group type: EXPERIMENTAL
Intervention: p16(INK4a) expression in undifferentiated pleomorphic sarcoma (UPS)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: p16(INK4a) expression in leiomyosarcoma
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: p16(INK4a) expression in synovial sarcoma
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: p16(INK4a) expression in liposarcoma
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: p16(INK4a) expression in angiosarcoma
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: p16(INK4a) expression in MPNST
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Loss of p16(INK4a) in high grade sarcomas
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Demethylation treatment with 5-aza-2'-deoxycytide
Number of subjects: 183
Study: 24747441

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 0
Study: 24747949

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² × 4 infusions) combined with three cycles of dexamethasone (28 mg/m², max. 40 mg) for 4 days at 2-week intervals
Number of subjects: 67

Group type: COMPARATOR
Intervention: Dexamethasone alone
Number of subjects: 67

Group type: COMPARATOR
Intervention: Rituximab alone
Number of subjects: 67

Group type: COMPARATOR
Intervention: Rituximab with one cycle of dexamethasone
Number of subjects: 67
Study: 24748496

Group type: EXPERIMENTAL
Intervention: Donor KIR B haplotypes
Number of subjects: 1532

Group type: EXPERIMENTAL
Intervention: Donor KIR B haplotypes with recipient C1-bearing HLA-C allotypes
Number of subjects: 1532

Group type: EXPERIMENTAL
Intervention: Two or more donor KIR B motifs with recipient C1
Number of subjects: 1532

Group type: COMPARATOR
Intervention: C1/x recipients
Number of subjects: 1532
Study: 24748824

Group type: EXPERIMENTAL
Intervention: New disposable injection pen (GoQuick(®), Pfizer, Inc.)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Current reusable pen (GENOTROPIN Pen(®), Pfizer, Inc.)
Number of subjects: 119
Study: 24750460

Group type: EXPERIMENTAL
Intervention: HeartMate II LVAD
Number of subjects: 1125
Study: 24750693

Group type: EXPERIMENTAL
Intervention: Parental self-efficacy scale for helping their child get at least 60 minutes of moderate intensity physical activity every day
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Parental self-efficacy scale for helping one's child consume five servings of fruits and vegetables each day
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Parental self-efficacy scale for limiting sugary drinks to once a week
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Parental self-efficacy scale for limiting consumption of fruit juice to 6 ounces every day
Number of subjects: 304
Study: 24751453

Group type: EXPERIMENTAL
Intervention: adalimumab 40 mg weekly for 45 weeks
Number of subjects: 11
Study: 24751516

Group type: EXPERIMENTAL
Intervention: Patients with a history of ischemic heart disease (IHD+)
Number of subjects: 4169

Group type: COMPARATOR
Intervention: Patients without a history of ischemic heart disease (IHD-)
Number of subjects: 4169

Group type: EXPERIMENTAL
Intervention: IHD+ patients
Number of subjects: 4169

Group type: COMPARATOR
Intervention: IHD- patients
Number of subjects: 4169
Study: 24752047

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 326

Group type: COMPARATOR
Intervention: Allogeneic hematopoietic stem-cell transplantation (allo-HSCT)
Number of subjects: 326
Study: 24752449

Group type: EXPERIMENTAL
Intervention: LY2523355 (litronesib) at 2 mg/m²/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LY2523355 (litronesib) at 4 mg/m²/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LY2523355 (litronesib) at 5 mg/m²/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LY2523355 (litronesib)
Number of subjects: 12
Study: 24752945

Group type: EXPERIMENTAL
Intervention: 4 cycles of cisplatin and gemcitabine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 81
Study: 24753053

Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Repeat stenting
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Implantation of a new stent
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Initial TIMI 3 flow at index ST
Number of subjects: 205
Study: 24753538

Group type: EXPERIMENTAL
Intervention: iC9-modified T cells
Number of subjects: 10
Study: 24753695

Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine (OCV) - 2 doses with a 2-week interval
Number of subjects: 20
Study: 24754273

Group type: EXPERIMENTAL
Intervention: IV abatacept (10 mg/kg weight-tiered dosing) with MTX (up to 8 mg/week)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: IV abatacept (10 mg/kg weight-tiered dosing) monotherapy
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: IV abatacept (10 mg/kg weight-tiered dosing) with and without background MTX
Number of subjects: 217
Study: 24754279

Group type: EXPERIMENTAL
Intervention: Nitinol stent implantation
Number of subjects: 196
Study: 24754280

Group type: EXPERIMENTAL
Intervention: EPIC self-expanding nitinol stent system
Number of subjects: 125
Study: 24754288

Group type: EXPERIMENTAL
Intervention: TruePath device
Number of subjects: 13
Study: 24754838

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100U
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24755158

Group type: EXPERIMENTAL
Intervention: Baseline measures from the BOLD cohort registry
Number of subjects: 5239

Group type: EXPERIMENTAL
Intervention: Healthcare site as a factor
Number of subjects: 5239
Study: 24755296

Group type: EXPERIMENTAL
Intervention: Capecitabine 750 mg/m2 twice a day during days 1-7, oxaliplatin 85 mg/m2 and bevacizumab 5 mg/kg on day 1, repeated every 14 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Capecitabine, oxaliplatin and bevacizumab combination
Number of subjects: 48
Study: 24755302

Group type: EXPERIMENTAL
Intervention: Left ventricular contrast injection with rotational C-arm CT (LV-RCT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Aortic contrast injection with rotational C-arm CT (Ao-RCT)
Number of subjects: 52
Study: 24755610

Group type: EXPERIMENTAL
Intervention: HFR cartridge
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HFR
Number of subjects: 12

Group type: COMPARATOR
Intervention: HD
Number of subjects: 12

Group type: COMPARATOR
Intervention: HFR and HD
Number of subjects: 12
Study: 24756302

Group type: EXPERIMENTAL
Intervention: Baseline clinical and laboratory features of IIH patients
Number of subjects: 165
Study: 24756512

Group type: EXPERIMENTAL
Intervention: STEMO weeks (ambulance-based thrombolysis)
Number of subjects: 6182

Group type: EXPERIMENTAL
Intervention: STEMO deployment
Number of subjects: 6182

Group type: EXPERIMENTAL
Intervention: STEMO weeks
Number of subjects: 6182
Study: 24756936

Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord-derived MSCs (UC-MSCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bone marrow-derived MSCs from patients with active lupus
Number of subjects: 0
Study: 24757132

Group type: EXPERIMENTAL
Intervention: Modified Disease Activity Score in 28 joints (M-DAS28)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified Simplified Disease Activity Index (M-SDAI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified Clinical Disease Activity Index (M-CDAI)
Number of subjects: 0
Study: 24757230

Group type: EXPERIMENTAL
Intervention: DiaPep277
Number of subjects: 457

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study: 24758395

Group type: EXPERIMENTAL
Intervention: Non-invasive electrical stimulation of nerves
Number of subjects: 25
Study: 24758527

Group type: EXPERIMENTAL
Intervention: FOLFIRI® + bevacizumab (5 mg/kg bevacizumab, 180 mg/m2 irinotecan, 400 mg/m2 bolus FU, 400 mg/m2 leucovorin, followed by 46-hour FU infusions (2400 mg/m2))
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: VEGFA polymorphism (rs25648)
Number of subjects: 62
Study: 24758722

Group type: EXPERIMENTAL
Intervention: Outpatient individual psychotherapy
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Step-down treatment program (including short-term day hospital treatment followed by combined group and individual psychotherapy)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Both treatment groups (Outpatient and Step-down)
Number of subjects: 113
Study: 24759933

Group type: EXPERIMENTAL
Intervention: Conventional tablets
Number of subjects: 132

Group type: COMPARATOR
Intervention: Chewable tablets
Number of subjects: 132

Group type: COMPARATOR
Intervention: Flavored powder
Number of subjects: 132

Group type: COMPARATOR
Intervention: Unflavored powder
Number of subjects: 132
Study: 24760136

Group type: COMPARATOR
Intervention: IVF
Number of subjects: 34

Group type: COMPARATOR
Intervention: OS alone or IVF
Number of subjects: 34
Study: 24760402

Group type: EXPERIMENTAL
Intervention: Dexmecamylamine 8 mg (normal renal function and mild renal impairment)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: TC-5412 2 mg (moderate renal impairment and ESRD)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dexmecamylamine (single oral dose)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 32
Study: 24760972

Group type: EXPERIMENTAL
Intervention: Cubans (n = 2128)
Number of subjects: 13285

Group type: EXPERIMENTAL
Intervention: Mexicans (n = 5371)
Number of subjects: 13285

Group type: EXPERIMENTAL
Intervention: Dominicans (n = 1217)
Number of subjects: 13285

Group type: EXPERIMENTAL
Intervention: Puerto Ricans (n = 2176)
Number of subjects: 13285

Group type: EXPERIMENTAL
Intervention: Central and South Americans (n = 1468 and 925, respectively)
Number of subjects: 13285
Study: 24761968

Group type: EXPERIMENTAL
Intervention: Bortezomib and rituximab (3 induction cycles of weekly administration)
Number of subjects: 42
Study: 24762806

Group type: EXPERIMENTAL
Intervention: Number of pacing stimuli needed to entrain (NNE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NNE with pacing cycle length and coupling interval
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NNE correlation with PPI and tachycardia cycle length
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NNE ≤2 and >3 predictions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Entrainment attempts changing or terminating tachycardia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NNE as a mapping criterion
Number of subjects: 30
Study: 24763770

Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive-behavioral therapy for depression
Number of subjects: 0
Study: 24763923

Group type: EXPERIMENTAL
Intervention: Recombinant FVIIa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 24763965

Group type: EXPERIMENTAL
Intervention: Statin therapy (n=186)
Number of subjects: 281

Group type: COMPARATOR
Intervention: No statin therapy (n=95)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 281
Study: 24764034

Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET/CT evaluation
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Steroid-based therapy (40 mg to 50 mg prednisone per day)
Number of subjects: 35
Study: 24764124

Group type: EXPERIMENTAL
Intervention: Veliparib (ABT-888) 40 mg twice daily on days 1-7 and temozolomide (TMZ) 150 mg/m(2)/day for cycle 1, then 200 mg/m(2)/day for cycle 2 onwards on days 1-5 q28 days.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Veliparib and TMZ combination treatment.
Number of subjects: 26
Study: 24764221

Group type: EXPERIMENTAL
Intervention: Galsulfase ERT
Number of subjects: 121
Study: 24765228

Group type: COMPARATOR
Intervention: Ingenol mebutate gel 0.01%
Number of subjects: 332
Study: 24766056

Group type: EXPERIMENTAL
Intervention: 1 week of alcohol withdrawal
Number of subjects: 47
Study: 24766669

Group type: EXPERIMENTAL
Intervention: Total Physical Activity (PA)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Unstructured Physical Activity (PA)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Watching TV and videos (Sedentary Behaviour)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Resting (Sedentary Behaviour)
Number of subjects: 468
Study: 24766766

Group type: EXPERIMENTAL
Intervention: Plant stanol ester (STAEST) intervention, doses varied from 0.8 to 8.8 g/d, duration from 4 to 52 weeks.
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Plant stanol ester (STAEST) intervention
Number of subjects: 868
Study: 24766985

Group type: EXPERIMENTAL
Intervention: Hospitalized patients with AF
Number of subjects: 9484

Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 9484

Group type: EXPERIMENTAL
Intervention: Heart rate at baseline
Number of subjects: 9484

Group type: EXPERIMENTAL
Intervention: AF symptom class
Number of subjects: 9484
Study: 24767767

Group type: EXPERIMENTAL
Intervention: Streptococcus OTU 1345
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Staphylococcus OTU 1348
Number of subjects: 55
Study: 24768093

Group type: EXPERIMENTAL
Intervention: Hormonal contraceptives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombosis prophylaxis during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of hereditary thrombophilia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Men
Number of subjects: 0
Study: 24768457

Group type: EXPERIMENTAL
Intervention: Handgrip strength intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 24768795

Group type: EXPERIMENTAL
Intervention: Acute ischemic stroke (AIS) patients
Number of subjects: 168
Study: 24768965

Group type: COMPARATOR
Intervention: African American ethnicity
Number of subjects: 12490
Study: 24769012

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (70-80% maximum volume of oxygen utilization) for 12 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (healthy parous women)
Number of subjects: 44
Study: 24769555

Group type: EXPERIMENTAL
Intervention: Absorb Bioresorbable Vascular Scaffold (Absorb BVS) system
Number of subjects: 512
Study: 24770443

Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC) procedures
Number of subjects: 42
Study: 24770461

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise task
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Feels-good task (self-selected intensity)
Number of subjects: 74